Dr. Neil Riordan on health: what the evidence says · JRE #1066
“Yeah, there's some really good animal data showing that you can inject these cells and you can take ovarian failure and reverse it. And in her case, she had an autoimmune disease and she was unable to have children... after treatment, she got pregnant pretty quickly.”
What the evidence says
Riordan described animal data showing mesenchymal stem cell injections can reverse ovarian failure, and cited one patient with an autoimmune-related fertility problem who conceived after treatment. Current peer-reviewed literature confirms extensive preclinical (rodent) evidence that mesenchymal stem cells or their derivatives can restore ovarian function and reduce granulosa cell apoptosis in chemically induced ovarian failure models. However, translation to humans remains at an early stage: a 2026 meta-epidemiological analysis found stem cell trials for premature ovarian failure are predominantly early-phase, single-center, and small-sample, with pregnancy-outcome data still sparse and unstandardized. No large randomized controlled trial has established that stem cell therapy reliably restores fertility or reverses ovarian failure in humans. A single patient's pregnancy following treatment is an anecdote that cannot be attributed to the intervention with any certainty, since spontaneous conception, misdiagnosis of ovarian failure, or other concurrent treatments cannot be ruled out without a controlled study. The claim accurately reflects the state of animal research but overstates its bearing on the individual human case presented as supporting evidence.
- Bridging the gap: meta-epidemiological analysis on the clinical translation of stem cell-based therapies in women's reproductive diseases (Human Reproduction Open, 2026) · government
- Insulin-like growth factor 1 as a key paracrine mediator in mesenchymal stem cell-based intervention for ovarian ageing: a review (Journal of Ovarian Research, 2026) · government